Review



siha  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC siha
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, <t>B)</t> <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1737 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/siha/product/ATCC
    Average 97 stars, based on 1737 article reviews
    siha - by Bioz Stars, 2026-05
    97/100 stars

    Images

    1) Product Images from "PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy"

    Article Title: PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

    Journal: Neoplasia (New York, N.Y.)

    doi: 10.1016/j.neo.2026.101305

    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Figure Legend Snippet: Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

    Techniques Used: Expressing



    Similar Products

    siha  (ATCC)
    97
    ATCC siha
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, <t>B)</t> <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/siha/product/ATCC
    Average 97 stars, based on 1 article reviews
    siha - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    cornin preparation siha  (ATCC)
    98
    ATCC cornin preparation siha
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, <t>B)</t> <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Cornin Preparation Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cornin preparation siha/product/ATCC
    Average 98 stars, based on 1 article reviews
    cornin preparation siha - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    cc cell lines  (ATCC)
    98
    ATCC cc cell lines
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, <t>B)</t> <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Cc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cc cell lines/product/ATCC
    Average 98 stars, based on 1 article reviews
    cc cell lines - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    human cervical squamous cell carcinoma cell lines siha  (ATCC)
    98
    ATCC human cervical squamous cell carcinoma cell lines siha
    HMGN1 inhibition affects the proliferation <t>of</t> <t>cervical</t> squamous cells. (A) mRNA and (B) protein expression levels of HMGN1 in <t>SiHa</t> and HeLa cells following siRNA transfection, compared with the NC. (C) Cell Counting Kit-8 assay assessing the proliferation of SiHa and HeLa cells at 24, 48 and 72 h. (D) Cell cycle distribution of SiHa and HeLa cells after HMGN1 inhibition was analyzed by flow cytometry, including flow cytometry plots and quantitative histograms. *P<0.05, **P<0.01 and ****P<0.001. HMGN1, high-mobility group nucleosome-binding protein 1; NC, non-targeting control; si, small interfering RNA.
    Human Cervical Squamous Cell Carcinoma Cell Lines Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cervical squamous cell carcinoma cell lines siha/product/ATCC
    Average 98 stars, based on 1 article reviews
    human cervical squamous cell carcinoma cell lines siha - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    human breast adenocarcinoma cells  (ATCC)
    98
    ATCC human breast adenocarcinoma cells
    HMGN1 inhibition affects the proliferation <t>of</t> <t>cervical</t> squamous cells. (A) mRNA and (B) protein expression levels of HMGN1 in <t>SiHa</t> and HeLa cells following siRNA transfection, compared with the NC. (C) Cell Counting Kit-8 assay assessing the proliferation of SiHa and HeLa cells at 24, 48 and 72 h. (D) Cell cycle distribution of SiHa and HeLa cells after HMGN1 inhibition was analyzed by flow cytometry, including flow cytometry plots and quantitative histograms. *P<0.05, **P<0.01 and ****P<0.001. HMGN1, high-mobility group nucleosome-binding protein 1; NC, non-targeting control; si, small interfering RNA.
    Human Breast Adenocarcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast adenocarcinoma cells/product/ATCC
    Average 98 stars, based on 1 article reviews
    human breast adenocarcinoma cells - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

    doi: 10.1016/j.neo.2026.101305

    Figure Lengend Snippet: Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

    Article Snippet: CC cell lines, including CaSki (ATCC Cat# CRM-CRL-1550_Ca Ski, RRID: CVCL_1100), SiHa (ATCC Cat# HTB-35_SiHa, RRID: CVCL_0032), and ME180 (ATCC Cat# HTB-33_ME-180, RRID: CVCL_1401), C33A (ATCC CRM-HTB-31, RRID:CVCL_1094) were obtained from ATCC.

    Techniques: Expressing

    HMGN1 inhibition affects the proliferation of cervical squamous cells. (A) mRNA and (B) protein expression levels of HMGN1 in SiHa and HeLa cells following siRNA transfection, compared with the NC. (C) Cell Counting Kit-8 assay assessing the proliferation of SiHa and HeLa cells at 24, 48 and 72 h. (D) Cell cycle distribution of SiHa and HeLa cells after HMGN1 inhibition was analyzed by flow cytometry, including flow cytometry plots and quantitative histograms. *P<0.05, **P<0.01 and ****P<0.001. HMGN1, high-mobility group nucleosome-binding protein 1; NC, non-targeting control; si, small interfering RNA.

    Journal: Oncology Letters

    Article Title: Lactylation-based machine algorithm combined with multi-omics analysis to predict prognosis in cervical cancer

    doi: 10.3892/ol.2026.15486

    Figure Lengend Snippet: HMGN1 inhibition affects the proliferation of cervical squamous cells. (A) mRNA and (B) protein expression levels of HMGN1 in SiHa and HeLa cells following siRNA transfection, compared with the NC. (C) Cell Counting Kit-8 assay assessing the proliferation of SiHa and HeLa cells at 24, 48 and 72 h. (D) Cell cycle distribution of SiHa and HeLa cells after HMGN1 inhibition was analyzed by flow cytometry, including flow cytometry plots and quantitative histograms. *P<0.05, **P<0.01 and ****P<0.001. HMGN1, high-mobility group nucleosome-binding protein 1; NC, non-targeting control; si, small interfering RNA.

    Article Snippet: Human cervical squamous cell carcinoma cell lines SiHa (cat. no. HTB-35) and HeLa (cat. no. CRM-CCL-2) were obtained from the American Type Culture Collection and the human keratinocyte cell line HaCaT was obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (SCSP-5091; Beijing, China).

    Techniques: Inhibition, Expressing, Transfection, Cell Counting, Flow Cytometry, Binding Assay, Control, Small Interfering RNA